Suzhou Union Biopharm

Suzhou Union Biopharm is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company utilizes a proprietary site-specific conjugation technology designed to enhance the stability, homogeneity, and therapeutic window of ADC candidates compared to traditional random conjugation methods. Its lead program, ALT-P7, is a HER2-targeting ADC developed in collaboration with Alteogen, currently undergoing clinical trials for breast and gastric cancers. Beyond its internal R&D efforts, Suzhou Union Biopharm operates as a CDMO, providing integrated services for the development and manufacturing of complex biologics and ADCs. The company's state-of-the-art facilities in the Suzhou Industrial Park support both early-stage research and GMP-compliant production.